Unite Labs automates life science labs in minutes instead of days

Better meat, better world

Impossible Foods makes delicious, nutritious meat from plants

Comply: Intelligent Pharmaceutical Process Management

Comply specializes in bridging Information Technology (IT) with regulatory requirements in the Life Science domain. Their wide expertise covers areas such as Quality Systems, Data Integrity, Validation of Computerized Systems, Quality of Digital Health systems, Cloud systems and more. Combining the professional services with best practice implementations enable operational excellence and help become a true knowledge-based organization. Comply delivers the highest quality standards by deploying an innovating, proactive approach to regulatory compliance across the full lifecycle of development, manufacturing and quality management processes.

34 days ago

Face2Gene app can diagnose rare diseases

Face2Gene is a suite of phenotyping applications that facilitate comprehensive and precise genetic evaluations. Face2Gene was developed by FDNA, the company, which is paving the way for clinicians to diagnose these diseases earlier, for labs to interpret genetic information more accurately and for life science researchers to make new discoveries to help develop rare disease therapies. As a confirmation, Face2Gene app increases the confidence of clinicians and bioinformatics by prioritizing genetic disorders and variants in the clinic and in the lab. This invention can detect phenotypes and reveal relevant facial and non-facial features.

34 days ago

TemperPack seeks to solve the world's packaging problems

TemperPack was founded in 2015 as a partnership between two friends from Maryland and a third colleague from school, the company was born out of a desire to reduce the amount of unsustainable packaging that correlated with the growing world of e-commerce delivery. Currently, TemperPack operates two facilities in Virginia and Nevada and is rapidly expanding its reach in the perishable and cold chain shipping market, all with the goal of reducing the amount of packaging that ends up in landfills. The company's main product ClimaCell™, which performs as well as EPS foam, and is certified curbside recyclable.

34 days ago

3B BlackBio provides a wide range of products and services in molecular testing

Fusing of the science of behavioural economics with real-world applications

Robotic rehabilitation solutions for patients suffering from a variety of neurological diseases

XEPTAGEN provides diagnostic solutions

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer (lat. Carcinoma) early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early-stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumour markers that lead to earlier and much more accurate detection of developing carcinomas. The company's mission is to include creating innovative tools that improve the clinical management of patients with liver, colorectal and prostate cancers (lat. Prostate Carcinoma).


Everwell: a user-centric technology for healthcare programs

Everwell Health Solutions is a Bangalore-based company that innovates, designs, builds and deploys user-centric technology for healthcare programs across the world. The company spun out of Microsoft Research India in 2015 by co-founders Andrew Cross and Bill Thies. Joined by Nakull Gupta, they began building a team in 2016 to champion their flagship work in digital adherence monitoring, 99DOTS, out of research and into large scale uptake in India. The company’s Everwell Hub is a comprehensive, integrated platform for adherence and patient management. Health care staff can log into a single portal to register and follow up with patients, whose adherence reports from any of its integrated technologies appear side-by-side including 99DOTS, evriMED devices, and VOT.


Diagnosing prostate cancer quickly and safely

Distinguishing between benign and malignant prostate tissue is difficult. A new device facilitates the diagnosis for doctors: Through visual analysis, they can reliably determine if they are dealing with carcinoma within a minute-and-a-half. Fraunhofer researchers have presented the prototype at the COMPAMED trade fair in Düsseldorf. Generally. doctors take a biopsy of prostate tissue from the patient to find out if it is carcinoma of the prostate – or a benign tissue change. In doing so, they insert a small needle into the prostate, using ultrasound images to assist with navigation. From the sample taken in this way, laboratory employees fabricate wafer-thin tissue sections – a laborious job that takes at least a day. Then, the tissue sections are forwarded to a pathologist, who examines them under the microscope. Even for experienced physicians, though, it is often difficult to distinguish between benign and malignant tissue.


Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.